TY - JOUR
T1 - Fecal microbiota transplantation for recurrent clostridium difficile infection and other conditions in children
T2 - A joint position paper from the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition
AU - Davidovics, Zev H.
AU - Michail, Sonia
AU - Nicholson, Maribeth R.
AU - Kociolek, Larry K.
AU - Pai, Nikhil
AU - Hansen, Richard
AU - Schwerd, Tobias
AU - Maspons, Aldo
AU - Shamir, Raanan
AU - Szajewska, Hania
AU - Thapar, Nikhil
AU - De Meij, Tim
AU - Mosca, Alexis
AU - Vandenplas, Yvan
AU - Kahn, Stacy A.
AU - Kellermayer, Richard
N1 - Funding Information:
The authors gratefully acknowledge the guidance and support of Dr Andrew Grossman in developing, drafting, and revising this article. The authors also gratefully acknowledge the following: Cures Within Reach (PI: Kahn), The Neil and Anna Rasmussen Foundation (PI: Kahn), and the Hamel Family (PI: Kahn), CTSA KL2 award, No.UL1 TR000445 (PI Hartmann), Wagner Family led Gutsy Kids Fund (PI: Kellermayer), and the Klaasmeyer family funds for Primary Sclerosing Cholangitis research (PI: Kellermayer).
Publisher Copyright:
© 2019 EDP Sciences. All rights reserved.
PY - 2019/1
Y1 - 2019/1
N2 - Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.
AB - Fecal microbiota transplantation (FMT) is becoming part of the treatment algorithms against recurrent Clostridium difficile infection (rCDI) both in adult and pediatric gastroenterology practice. With our increasing recognition of the critical role the microbiome plays in human health and disease, FMT is also being considered as a potential therapy for other disorders, including inflammatory bowel disease (Crohn disease, ulcerative colitis), graft versus host disease, neuropsychiatric diseases, and metabolic syndrome. Controlled trials with FMT for rCDI have not been performed in children, and numerous clinical and regulatory considerations have to be considered when using this untraditional therapy. This report is intended to provide guidance for FMT in the treatment of rCDI in pediatric patients.
KW - child
KW - Clostridium difficile
KW - fecal
KW - fecal transplantation
KW - microbiome
KW - microbiota
KW - pediatric
UR - http://www.scopus.com/inward/record.url?scp=85059225507&partnerID=8YFLogxK
U2 - 10.1097/mpg.0000000000002205
DO - 10.1097/mpg.0000000000002205
M3 - Article
C2 - 30540704
SN - 0277-2116
VL - 68
SP - 130
EP - 143
JO - Journal of Pediatric Gastroenterology and Nutrition
JF - Journal of Pediatric Gastroenterology and Nutrition
IS - 1
ER -
